DE602005017181D1 - Kombinationen mit epothilonen und protein-tyrosin-kinasehemmern sowie pharamazeutische verwendung dafür - Google Patents

Kombinationen mit epothilonen und protein-tyrosin-kinasehemmern sowie pharamazeutische verwendung dafür

Info

Publication number
DE602005017181D1
DE602005017181D1 DE602005017181T DE602005017181T DE602005017181D1 DE 602005017181 D1 DE602005017181 D1 DE 602005017181D1 DE 602005017181 T DE602005017181 T DE 602005017181T DE 602005017181 T DE602005017181 T DE 602005017181T DE 602005017181 D1 DE602005017181 D1 DE 602005017181D1
Authority
DE
Germany
Prior art keywords
tyrosine kinase
protein tyrosine
epothilones
combinations
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005017181T
Other languages
English (en)
Inventor
Jerry Min-Jian Huang
Anandhi Ranganathan Johri
Ronald Richard Linnartz
Paul M Mcsheehy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005017181(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of DE602005017181D1 publication Critical patent/DE602005017181D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005017181T 2004-11-30 2005-11-28 Kombinationen mit epothilonen und protein-tyrosin-kinasehemmern sowie pharamazeutische verwendung dafür Active DE602005017181D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63183704P 2004-11-30 2004-11-30
PCT/US2005/042975 WO2006060331A1 (en) 2004-11-30 2005-11-28 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
DE602005017181D1 true DE602005017181D1 (de) 2009-11-26

Family

ID=36118322

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017181T Active DE602005017181D1 (de) 2004-11-30 2005-11-28 Kombinationen mit epothilonen und protein-tyrosin-kinasehemmern sowie pharamazeutische verwendung dafür

Country Status (29)

Country Link
US (2) US20080139587A1 (de)
EP (1) EP1819331B1 (de)
JP (1) JP2008521826A (de)
KR (1) KR20070088653A (de)
CN (1) CN101065127A (de)
AT (1) ATE445398T1 (de)
AU (1) AU2005312061B2 (de)
BR (1) BRPI0518733A2 (de)
CA (1) CA2584163A1 (de)
CY (1) CY1110559T1 (de)
DE (1) DE602005017181D1 (de)
DK (1) DK1819331T3 (de)
ES (1) ES2333348T3 (de)
HK (1) HK1109059A1 (de)
HR (1) HRP20100012T1 (de)
IL (1) IL183138A (de)
JO (1) JO2596B1 (de)
MA (1) MA29032B1 (de)
MX (1) MX2007006371A (de)
NO (1) NO20073370L (de)
NZ (1) NZ554552A (de)
PL (1) PL1819331T3 (de)
PT (1) PT1819331E (de)
RU (1) RU2423980C2 (de)
SI (1) SI1819331T1 (de)
TN (1) TNSN07212A1 (de)
TW (1) TW200630091A (de)
WO (1) WO2006060331A1 (de)
ZA (1) ZA200703196B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6220126B2 (ja) 2009-11-23 2017-10-25 セルリアン・ファーマ・インコーポレイテッド 治療的送達のためのシクロデキストリンに基づく重合体
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
CN102134246A (zh) * 2011-01-06 2011-07-27 王文怡 一种埃博霉素衍生物及其制备和药物应用
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2879675B1 (de) 2012-08-06 2019-11-13 Duke University Auf hsp90 gerichtete verbindungen und verfahren
WO2015148714A1 (en) 2014-03-25 2015-10-01 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
EP3826988A4 (de) 2018-07-24 2023-03-22 Hygia Pharmaceuticals, LLC Verbindungen, derivate und analoga für krebs
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
EP4192509A1 (de) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Behandlung von krebs mit einem cyclodextrinhaltigen polymer-topoisomerase-inhibitor-konjugat und einem parp-inhibitor
GB2617409A (en) 2022-04-27 2023-10-11 Cancertain Ltd Method for predicting responsiveness to therapy
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
JP4499359B2 (ja) * 2001-02-27 2010-07-07 ノバルティス アーゲー シグナル変換阻害剤とエポチロン誘導体とを含有してなる組合せ剤
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
ATE476995T1 (de) * 2002-06-10 2010-08-15 Novartis Pharma Gmbh Epothilone enthaltende kombinationen und deren pharmazeutische verwendungen
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
NZ554552A (en) 2011-05-27
EP1819331A1 (de) 2007-08-22
RU2007124492A (ru) 2009-04-10
DK1819331T3 (da) 2010-01-04
US20080139587A1 (en) 2008-06-12
AU2005312061A1 (en) 2006-06-08
HK1109059A1 (en) 2008-05-30
BRPI0518733A2 (pt) 2008-12-02
SI1819331T1 (sl) 2010-02-26
MA29032B1 (fr) 2007-11-01
PT1819331E (pt) 2009-11-30
ES2333348T3 (es) 2010-02-19
MX2007006371A (es) 2007-06-20
JP2008521826A (ja) 2008-06-26
TW200630091A (en) 2006-09-01
PL1819331T3 (pl) 2010-03-31
KR20070088653A (ko) 2007-08-29
WO2006060331A1 (en) 2006-06-08
TNSN07212A1 (en) 2008-11-21
CA2584163A1 (en) 2006-06-08
IL183138A0 (en) 2008-04-13
EP1819331B1 (de) 2009-10-14
CN101065127A (zh) 2007-10-31
HRP20100012T1 (hr) 2010-02-28
CY1110559T1 (el) 2015-04-29
ATE445398T1 (de) 2009-10-15
US20110190312A1 (en) 2011-08-04
NO20073370L (no) 2007-06-29
IL183138A (en) 2011-03-31
JO2596B1 (en) 2011-02-27
RU2423980C2 (ru) 2011-07-20
AU2005312061B2 (en) 2009-09-03
ZA200703196B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
ATE445398T1 (de) Kombinationen mit epothilonen und protein-tyrosin-kinasehemmern sowie pharamazeutische verwendung dafür
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
MX2019005150A (es) Inhibidores de la tirosina-cinasa de bruton.
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE602007004092D1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
EA200801430A1 (ru) Производные триазола
BRPI0614481A2 (pt) composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5
WO2007086943A3 (en) Wortmannin conjugates and uses thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN